Globalization vs Deglobalization
China's Biotech Licensing Boom Is Reaching the Income Statement. Is That Sustainable?
China's Biotech Financing Was Already Changing. What Will COINS Add?
BINSA and the WuXi AppTec Case: Two Distinct Tracks in U.S. Biotech National Security Policy
From Aiolos to Kailera: Who Captures the Value in a China-to-Global NewCo?
Clinical Going Global: Why Australia and Europe Matter More for Chinese Biotech